Drug
Cotadutide clinical trials
Also written MEDI0382.
- studies test it
- 23
- open now
- 0
- in phase 3
- 0
- first study started
- 2015
How studies write it
Studies that test it under each name
Development codes
- MEDI0382
- 13
Studies by the year they started
23 studies that test it; most in 2018 (7)
| Year | Studies |
|---|---|
| 2015 | 2 |
| 2017 | 5 |
| 2018 | 7 |
| 2019 | 2 |
| 2020 | 2 |
| 2022 | 4 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 12
- Phase 2
- 12
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 23 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses cotadutide is read from its arms, and is right about nine times in ten.
Testing it · 23
- A Study to Evaluate the Safety and Efficacy of Cotadutide Given by Subcutaneous Injection in Adult Participants With Non-cirrhotic Non-alcoholic Steatohepatitis With FibrosisCompletedPhase 2AstraZenecaNCT05364931Written as Cotadutide
- A Randomised, Open-Label Study to Evaluate the Relative and Absolute Bioavailability of Cotadutide in Healthy SubjectsCompletedPhase 1AstraZenecaNCT05294458Written as cotadutide solution for injection
- A Study of Cotadutide in Participants Who Have Chronic Kidney Disease With Type 2 Diabetes MellitusCompletedPhase 2AstraZenecaNCT04515849Written as Cotadutide 100 micrograms
- A Study to Investigate the Effect of MEDI0382 on Hepatic Glycogen Metabolism in Overweight and Obese Subjects With Type 2 Diabetes Mellitus.CompletedPhase 2MedImmune LLCNCT03555994Written as MEDI0382
- Chinese Multiple Dose Escalation (MDE) High Dose StudyCompletedPhase 1AstraZenecaNCT05437848Written as Experimental: Cotadutide
- A Thorough QTC Study to Assess the Effect of Cotadutide on Cardiac Repolarization in Healthy ParticipantsTerminatedPhase 1AstraZenecaNCT05668936Written as Cotadutide
- Pharmacokinetics of Cotadutide in Participants With Hepatic ImpairmentTerminatedPhase 1AstraZenecaNCT05517226Written as Cotadutide
- A Study to Evaluate the Effect of MEDI0382 on Energy Balance in Overweight and Obese Participants With Type 2 Diabetes MellitusCompletedPhase 2MedImmune LLCNCT03596177Written as MEDI0382
- A Study to Evaluate Safety and Pharmacodynamic Efficacy of 0382 in Obese Subjects With NAFLD/NASH.CompletedPhase 2MedImmune LLCNCT04019561Written as MEDI0382 high dose
- A Study to Assess Safety, Tolerability, and Pharmacokinetics of MEDI0382 in Non-diabetic Obese ParticipantsCompletedPhase 1MedImmune LLCNCT03625778Written as MEDI0382
- A Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 DiabetesCompletedPhase 2AstraZenecaNCT03235050Written as MEDI0382 low dose
- Safety and Tolerability Study of Cotadutide in Japanese Obese Subjects With Type 2 Diabetes MelitusCompletedPhase 1AstraZenecaNCT04208620Written as Cotadutide
- A Study to Evaluate the Safety and Tolerability of MEDI0382 in Overweight and Obese Participants With Type 2 Diabetes MellitusCompletedPhase 2MedImmune LLCNCT03745937Written as MEDI0382
- A Study to Look at the Effect MEDI0382 Has on Blood Sugar in People With Type 2 Diabetes and Kidney Problems and Also to Check That MEDI0382 is Well ToleratedCompletedPhase 2MedImmune LLCNCT03550378Written as MEDI0382
- Study of MEDI0382 in Combination With Dapagliflozin and Metformin in Overweight/Obese Participants With Type 2 DiabetesCompletedPhase 2MedImmune LLCNCT03444584Written as MEDI0382
- Safety and Tolerability Study of MEDI0382 in Japanese Preobese or Obese Subjects With Type 2 DiabetesCompletedPhase 2AstraZenecaNCT03645421Written as MEDI0382 100 μg
- A Study to Investigate Different Doses of 0382 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus.CompletedPhase 2MedImmune LLCNCT03244800Written as MEDI0382
- A Study to Evaluate the Safety and Pharmacokinetics of MEDI0382 in Overweight/Obese Subjects of Japanese or Chinese DescentCompletedPhase 1MedImmune LLCNCT03385369Written as MEDI0382
- A Multiple-ascending-dose Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of MEDI0382 in Overweight and Obese Participants With Type 2 Diabetes MellitusCompletedPhase 1/2MedImmune LLCNCT02548585Written as MEDI0382
- A Study to Evaluate Pharmacokinetics, Safety and Tolerability of MEDI0382 in Renal Impairment SubjectsCompletedPhase 1MedImmune LLCNCT03235375Written as MEDI0382
Codes
What other systems call cotadutide · ClinicalTrials.gg INT000820
- MeSH (NLM) C000624433cotadutideOne source NLM
- UNII (FDA) QL6A9B13HWCOTADUTIDEConfirmed FDA, NLM, Wikidata
- Wikidata Q105592669cotadutideConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C174890CotadutideOne source FDA
- DrugBank DB15194One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000624433 | cotadutide | One source NLM |
| UNII (FDA) | QL6A9B13HW | COTADUTIDE | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q105592669 | cotadutide | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C174890 | Cotadutide | One source FDA |
| DrugBank | DB15194 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.